The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-18 and is reviewed periodically as new material appears.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Currently, no over-the-counter weight-loss supplements have met criteria for recommended use by physicians. Dexatrim claims to provide a powerful benefit for weight loss despite the lack of scientific data to support their claims. Dexatrim further provides a disclaimer that no claims of efficacy and safety made by Dexatrim have been approved by the FDA. Although available OTC, the active ingredients in Dexatrim products carry risk of side effects, adverse reactions and adverse drug interactions, particularly if used at high-recommended or higher-than-recommended doses and/or for prolonged periods. The Dexatrim product itself carries a warning about the possible side effects of Dexatrim in patients with a history of high blood pressure, and also recommends the advice of a qualified physician before taking Dexatrim. In addition, the use of Dexatrim or other OTC weight-loss supplements presents a possible factor in establishing disruptive eating patterns, increases the risk that individuals will use these OTC supplements in lieu of seeking proper medical and nutritional consultation, and presents increased psychological risks associated with unsuccessful weight-loss attempts.
CCL7 is a multipotent chemokine involved in anti-bacterial, anti-viral and anti-fungal immune responses. For example, CCL7-mediated stimulation of CCR2 chemokine receptors on monocytes is participating in the elimination of Listeria monocytogenes infections by the recruitment of monocytes and TNF/iNOS-producing dendritic cells (TipDCs). Next, the role of the CCL7 was also observed in the mouse infected by West Nile Virus. The genetically deficient mice in CCL7 have increased mortality because of decrease in monocytes and neutrophils. Early induction of CCL7 downstream of TLR9 signaling also promotes the development of robust immunity to cryptococcal infections. Diseases associated with CCL7 dysregulation are observed. For example, an abnormal increase of CCL7 worsens many disorders, like HIV or lesional psoriasis. Furthermore, CCL7 is implicated in various immunological diseases, as ulcerative colitis, multiple sclerosis or nonatopic and atopic asthma. It seems, that the expression of CCL7 can activate an antitumor immune response.
The formation of chain structures has a direct impact on the overall strength of the whole polymer; the longer a chain is, the more differing the effects amylopectin will have on starch's morphology. Packing of chains, inter block chain length (IB-CL), also correlates with the gelatinization temperature of starch granules. In tandem, the IB-CL will increase as the length of B chains increases, meaning that as the length of individual B chains increases, so does the blocks between connections with other chains. Finally, in general, the more densely packed the resulting molecule of amylopectin, the higher the strength of the starch gel as a whole unit. Starch utilizes the density-strength correlation of amylopectin as a measure of forming dense, strong bricks as a basis for the final starch configuration. Amylopectin in starch is formed into helices to compose hexagonal structures that will subsequently be differentiated into A (cereal) and B (high-amylose; tubular) type starch. Structurally, A is more compact, while B is looser, hence the higher concentration of amylose.
Bismuth has few commercial applications, and those that use it generally require small quantities relative to other raw materials. In the United States, for example, 733 tonnes of bismuth were consumed in 2016, of which 70% went into chemicals (including pharmaceuticals, pigments, and cosmetics) and 11% into bismuth alloys.
Dasiglucagon demonstrates pharmacological effects consistent with glucagon, except for the freezing deficiency observed in rats (specific to rats and occurring simultaneously with glucagon and dasiglucagon) and the accumulation of liver glycogen in non-diabetic animals with obvious hyperglycemia and hyperinsulinemia.
Sources: en.wikipedia.org
==== Teleostei ==== Order Anabantiformes Betta splendens, Siamese fighting fish (2018) Helostoma temminkii, Kissing gourami (2020) Order Anguilliformes Anguilla anguilla, European Eel (2012) Anguilla japonica, Japanese Eel (2022) Order Atheriniformes Atherinopsis californiensis, Jack silverside (2023) Order Beloniformes Oryzias latipes, medaka (2007) Order Callionymiformes Callionymus lyra, common dragonet (2020) Order Carangiformes Caranx ignobilis, Giant trevally (2022) Caranx melampygus, Bluefin trevally (2021) Pseudocaranx georgianus, New Zealand trevally (2021) Order Centrarchiformes Oplegnathus fasciatus, barred knifejaw (2019) Siniperca roulei (Slender Mandarinfish) (2025) Order Characiformes Astyanax jordani, Mexican cavefish (2014) Astyanax mexicanus, Mexican tetra (2021) Colossoma macropomum, Tambaqui (2021) Hasemania nana, Silvertip tetra (2013) Hyphessobrycon heterorhabdus, Flag tetra (2023) Petitella bleheri, Firehead tetra (2015) Psalidodon paranae, (2016) Order Cichliformes Oreochromis niloticus, Nile tilapia (2019) Maylandia zebra, Lake Malawi cichlid (2019) Order Clupeiformes Clupea harengus, Atlantic herring (2020) Coilia nasus, Japanese grenadier anchovy (2020) Sardina pilchardus, European pilchard (2019) Order Cypriniformes Anabarilius grahami, Kanglang fish (2018) Danio rerio, zebrafish (2007) Leuciscus baicalensis, Siberian dace (2014) Megalobrama amblycephala, Wuchang bream (2017) Metzia formosae, (2015) Opsarius caudiocellatus, (2022) Oxygymnocypris stewartii, (2019) Pseudobrama simoni (2020) Rhodeus ocellatus, Rosy bitterling (2020) Triplophysa bleekeri, Tibetan stone loach (2020) Order Cyprinodontiformes Fundulus catenatus, Northern studfish (2020) Fundulus olivaceus, Blackspotted topminnow (2020) Fundulus nottii, Bayou topminnow (2020) Fundulus xenicus, Diamond killifish (2020) Gambusia affinis, western mosquitofish (2020) Heterandria formosa, least killifish (2019) Micropoecilia picta, swamp guppy (2021) Xiphophorus maculatus, platyfish (2013) Nothobranchius furzeri, turquoise killifish (2015) Order Esociformes Esox lucius, northern pike (2014) Order Gadiformes Gadus macrocephalus, Pacific cod (2022) Gadus morhua, Atlantic cod (2011) Order Gasterosteiformes Gasterosteus aculeatus, three-spined stickleback (2006, 2012) Order Gobiiformes Oxyeleotris marmorata, marble goby (2020) Periophthalmus modestus, shuttles hoppfish or shuttles mudskipper (2022) Order Gymnotiformes Electrophorus electricus, electric eel (2014) Order Lampriformes Lampris incognitus, Smalleye Pacific Opah (2021) Order Osmeriformes Neosalanx tangkahkeii, Chinese icefish (2015) Protosalanx hyalocranius, clearhead icefish (2017) Order Osteoglossiformes Heterotis niloticus, African arowana (2020) Paramormyrops kingsleyae, mormyrid electric fish (2017) Scleropages formosus, Asian arowana (2016) Order Perciformes Centropyge bicolor, bicolor angelfish (2021) Chaetodon trifasciatus, melon butterflyfish (2020) Channa argus, northern snakehead (2017) Channa maculata, blotched snakehead (2021) Chelmon rostratus, copperband butterflyfish (2020) Chrysiptera cyanea, Sapphite damselfish (2024) Dissostichus mawsoni, Antarctic toothfish (2019) Eleginops maclovinus, Patagonian robalo (2019) Epinephelus moara, kelp grouper (2021) Larimichthys crocea, large yellow croaker (2014) Lutjanus campechanus, Northern red snapper (2020) Naso vlamingii, bignose unicornfish (2020) Parachaenichthys charcoti, Antarctic dragonfish (2017) Rachycentron canadum, Cobia (2024) Seriola dumerili, Greater amberjack (2017) Sillago sinica, chinese sillago (2018) Siniperca knerii, Big-Eye Mandarin Fish (2020) Sparus aurata, gilt-head bream (2018) Holacanthus passer, King Angelfish (2024) Oplegnathus fasciatus, Barred knifejaw (2024) Order Pleuronectiformes Microstomus kitt, Lemon sole (2025) Order Salmoniformes Salmo salar, Atlantic salmon (2016) Oncorhynchus mykiss, rainbow trout (2014) Oncorhynchus tshawytscha, Chinook salmon (2018) Salvelinus namaycush, Lake Trout (2021) Order Scorpaeniformes Sebastes schlegelii, Black rockfish (2018) Order Siluriformes Clarias batrachus, walking catfish (2018) Ictalurus punctatus, channel catfish (2016) Pangasianodon hypophthalmus, Iridescent shark catfish (2021) Silurus glanis, Wels catfish (2020) Order Spariformes Datnioides pulcher, Siamese tigerfish (2020) Datnioides undecimradiatus, Mekong tiger perch (2020) Order Syngnathiformes Syngnathus scovelli, Gulf pipefish (2016, 2023) Entelurus aequoreus, Snake pipefish (2024) Order Tetraodontiformes Diodon holocanthus, Long-spine porcupinefish (2020) Mola mola, ocean sunfish (2016) Takifugu rubripes, a puffer fish (2002) Tetraodon nigroviridis, a puffer fish (2004)
Tribenoside (Glyvenol) is a vasoprotective drug used to treat hemorrhoids. It has mild anti-inflammatory, analgesic, and wound healing properties. Tribenoside stimulates laminin α5 production and laminin-332 deposition to help repair the basement membrane during the wound healing process. It is a mixture of the α- and β-anomers. Tribenoside has been shown to induce drug hypersensitivity syndrome in association with CMV reactivation.
== Video games == Games created during this time period often used a motif of nuclear war, as was the threat at that time. Some of the games listed have been made after the conclusion of the Cold War, but feature a central plot point around the Cold War.
Wood is an organic material and decays under biological and chemical degradation when buried or submerged above water or soil. Wood, an organic material produced by plants, are chemically composed of: carbohydrates (cellulose and hemicellulose), lignin and other components (aliphatic acids, alcohols, proteins and inorganic substances) in a smaller amount. The most important composition of the plant is the cellulose. The cellulose accounts for the majority of the cell, about 40% to 50% of the wood's total mass. Hemicellulose represents the second most important carbohydrate and accounts for 20% to 30% of the wood's cell. In cases of extreme wetness or dryness, wood can be preserved until the extreme environment is disrupted. Conservation of wooden waterlogged objects is dependent on the natural wood type and biological structure. Wood is separated into two categories, hardwoods and softwoods. The category the waterlogged wood falls into can determine the amount of porous absorption. Hardwoods are classified as angiosperms. Angiosperms are considered porous woods because of the vessel pores. Softwoods are gymnosperms and are considered non-porous because of the lack of vessel pores. The type of wood and the availability of vessel pores largely affect how conservators treat and preserve waterlogged wood. Waterlogged wood objects can be found in a range of excavations sites. For example, waterlogged wood is something an archaeologist might stumble upon during an excavation either from the wood being submerged or near water or being in moist soil over time.
== Career == Sinclair met Massachusetts Institute of Technology professor Leonard P. Guarente in 1993. Guarente had studied yeast as a model of aging, and after meeting him, Sinclair interviewed for a post-doc position in Guarente's lab. He worked as a postdoctoral researcher for Guarente for four years and in 1999 he was hired at Harvard Medical School. In 2004, Sinclair met with the philanthropist Paul F. Glenn who donated $5 million to Harvard to establish the Paul F. Glenn Laboratories for the Biological Mechanisms of Aging at Harvard, of which Sinclair became the founding director. In 2004, Sinclair founded Sirtris Pharmaceuticals along with Andrew Perlman, Christoph Westphal, Richard Aldrich, Richard Pops, and Paul Schimmel. Sirtris was focused on developing Sinclair's research into activators of sirtuins, work that began in the Guarente lab. The company was specifically focused on resveratrol formulations and derivatives as activators of the SIRT1 enzyme; Sinclair became known for making statements about resveratrol like: "(It's) as close to a miraculous molecule as you can find. ... One hundred years from now, people may be taking these molecules on a daily basis to prevent heart disease, stroke, and cancer." Most of the anti-aging field was more cautious, especially with regard to what else resveratrol might do in the body and its lack of bioavailability. The company went public in 2007 and was subsequently purchased by and made a subsidiary of GlaxoSmithKline in 2008 for $720 million.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.